The Advances in Novel Delivery Strategies for Hirudin Against Cardiovascular Diseases

Area of Science:

• Biomedical Engineering
• Pharmacology
• Cardiovascular Medicine

Background:

• Hirudin, a natural polypeptide, is a direct thrombin inhibitor with anticoagulant, anti-myocardial fibrotic, and anti-inflammatory properties beneficial for cardiovascular diseases (CVD).
• Clinical use of hirudin is constrained by low bioavailability, poor targeting, and bleeding risks.
• Nanotechnology offers advanced peptide drug delivery systems to overcome these limitations.

Purpose of the Study:

• To review the mechanisms, clinical applications, and novel delivery strategies of hirudin for CVD treatment.
• To highlight recent advancements in hirudin-based drug delivery systems.
• To explore future research directions for optimizing hirudin delivery.

Main Methods:

• Systematic review of existing literature on hirudin and drug delivery systems for CVD.
• Analysis of nanotechnology applications in enhancing hirudin's therapeutic efficacy.
• Discussion of challenges and future prospects in hirudin delivery system development.

Main Results:

• Hirudin-based drug delivery systems show significant potential in improving drug stability in vivo, enhancing targeting, and enabling responsive release.
• Nanotechnology addresses key limitations of hirudin, improving its therapeutic effectiveness for CVD.
• Advancements focus on overcoming bioavailability and targeting issues.

Conclusions:

• Hirudin-based nanodelivery systems represent a promising strategy for safe and efficient CVD treatment.
• Future directions include developing intelligent carriers, real-time feedback systems, and standardized evaluation methods.
• Optimized hirudin delivery systems are crucial for advancing cardiovascular disease therapy.